Effect of postmenopausal estrogen replacement therapy on lipoproteins

International Journal of Gynecology and Obstetrics

Volumn 52, Issue 2, 1996, Pages 155-161

  Omu, A E ^a,b   Al Qattan, N ^a,b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Kuwait Maternity Hospital   (Kuwait)

Author keywords

Hormone therapy; Lipoprotein changes; Postmenopausal

Indexed keywords

CHOLESTEROL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORGESTREL; PREMPAK; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HIGH RISK POPULATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030045463     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/0020-7292(95)02578-2     Document Type: Article

References (25)

1. Daly E, Roche M, Barton D, Gray A, McPherson K, Vessey M. HRT: an analysis of benefits, risks and cost in hormone replacement therapy. Br Med Bull 1992; 48(2): 249.
2. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease: the Framingham study. Ann Intern Med 1978; 89: 157.
3. Fortherby K. Oral contraceptives, lipids and cardiovascular disease. Contraception 1985; 31: 367.
4. Kloosterboer HJ, Van Wayjen RGA, Van den Ende A. Comparative effects of monophasic desogestrel plus ethinylestradiol and triphasic levonorgestrel plus ethinylestradiol on lipid metabolism. Contraception 1986; 34: 135.
5. Bush TL, Barrett-Connor E, Cowan L, Criqui MH. Wallace RB, Suchindran CM et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: results from lipid research clinics program follow-up study. Circulation 1987; 75: 1102.
6. Jick A, Dlinan B, Rothman K New contraceptive estrogen and new fatal myocardial infarction. J Am Med Assoc 1978; 139: 1407.
7. Paganini-Hill A, Ross R, Henderson B. Post-menopausal oestrogen treatment and stroke: a prospective study Br Med J 1988; 297: 519.
8. Baber R, Abdalla H, Studd J. The premature menopause. In: Studd JWW, editor, Churchill Livingstone, London. Progress in Obstetrics and Gynaecology, Vol. 9. 1989: 209.
9. Henderson BE, Ross RK, Lobo RA, Pike MC, Mack TM. Reevaluating the role of progestogen therapy after menopause. Fertil Steril 1988; 49 (Suppl.): 95.
10. European Atherosclerosis Society Study Group. The recognition and management of hyperlipidemia in adults. A policy statement of the European Atherosclerosis Society on management of hyperlipdemia in adults. Eur Heart J 1988; 9: 571.
11. Matthew HA, Meilahn E, Huller LH, Helsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641.
12. Bush T, Cowan L, Heiss G, Chambliss L, Wallace R. Ovarian function and lipid lipoprotein levels: results from the lipid research clinics program. Am J Epidemiol 1984; 120: 489.
13. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321.
14. Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkin BM, Schonfield G et al. Lipoprotein-cholesterol distribution in selected North American populations. The lipid research clinics program prevalence study. Circulation 1980; 61: 302.
15. Connor SL, Connor WE, Sexton G, Calvin L, Bacon S. The effects of age, body weight and family relationships on plasma lipoproteins and lipids in men, women and children of randomly selected families. Circulation 1982; 65: 1290.
16. Rosenberg L, Henne Kens CH, Rosner B, Bellanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47.
17. Sullivan KV, van der Zwagg R, Hughes JP. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988; 108: 358.
18. McFarland KF, Boniface ME, Hornung CA. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J 1989; 117: 1209.
19. Hjortland MC, McNamara PM, Kannel WB. Some atherogenic concomitants of menopause: the Framingham study. Am J Epidemiol 1976; 103: 304-311.
20. Lindquist O, Bengtsson C. Serum lipids, arterial blood pressure and body weight in relation to the menopause: results from a population of women in Göteborg, Sweden. Scand J Clin Lab Invest 1980; 40: 629-636.
21. Tikannen MJ, Kuusi T, Mikkila EA, Sipinen S. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins. A review. Maturitas 1986; 8: 7.
22. Lobo RA, Whitehead M. Too much of a good thing? Use of progestogen in the menopause: an international consensus statement. Fertil Steril 1989; 51: 229.
23. Fletcher CD, Farish E, Hart DM, Leggate J, Clark DM, Kitchener H et al. Effect on lipoproteins of Trisequens, a combined hormone preparation. Maturitas 1984; 6: 279.
24. Saure A, Hirvonen E, Tikamen MJ, Viinikka L, Ylikorkala O. A novel oestradiol-desogestrel preparation for hormone replacement therapy: effects on hormones, lipids, bone, climacteric symptoms and endometrium. Maturitas 1993; 16: 1.
25. Christiansen C, Riis BJ. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoprotein, and bleeding pattern. Br J Obstet Gynaecol 1990; 97: 1087.